SAN DIEGO — Vektor Medical announced that its non-invasive arrhythmia mapping system, vMap®, has now been used in over 2,000 procedures across the United States—a significant milestone highlighting increasing adoption among electrophysiologists and hospitals aiming to improve cardiac ablation outcomes and procedural efficiency.
Designed with AI, vMap localizes both focal and fibrillation-type arrhythmias in all four chambers of the heart in under a minute. Clinical studies have shown that the system can reduce procedure time, lower fluoroscopy exposure, and potentially minimize the need for repeat interventions. Currently in use at more than 20 hospitals nationwide, vMap integrates seamlessly with existing EP lab infrastructure.
“vMap has become an integral part of how I care for patients,” said Dr. Anish Amin, Section Chief of Electrophysiology at OhioHealth Heart and Vascular. “It’s efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients.”
As pulsed field ablation (PFA) sees growing clinical interest, tools like vMap are gaining relevance for their ability to provide fast, accurate, and accessible arrhythmia data. The system supports improved targeting both before and during procedures, enhancing the precision and effectiveness of PFA treatments.
“This milestone represents meaningful momentum,” said Robert Krummen, CEO of Vektor Medical. “With every procedure, physicians are leveraging vMap’s rapid, non-invasive insights to make informed decisions and streamline care. We’re seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care.”
vMap is FDA-cleared and commercially available in the U.S. Vektor Medical plans to further validate the platform’s clinical impact through ongoing studies, including the upcoming IMPRoVED-AF trial, while continuing to expand its footprint through strategic partnerships and innovation in arrhythmia care.
